First experience with the application of rituximab for the treatment of patients with sjogren's syndrome and disease

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 2, 2009, Pages 3-10

  Vasiliev, V I ^a   Logvinenko, O A ^a   Kokosadze, N V ^a   Gaiduk, I V ^a   Varlantova, E Yu ^a   Kovrigina, A M ^a   Gorodetsky, V R ^a   Nasonov, E L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65249131178     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Russian source
2. Russian source
3. Kassan S. S., Thomas T. L., Moutsopoulos H. M. et al. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med. 1978; 89: 888-892.
4. Voulgarelis M., Dafni U. G., Isenberg D. A. et al. Malignant lymphoma in primary Sjogren's syndrome. A multicenter, retrospective, clinical study by the European Concerted Action on Sjören's syndrome. Arthr. and Rheum. 1999; 42: 1765-1772.
5. Russian source
6. Harris N. L. Lymphoid proliferations of the salivary glands. Am. J. Clin. Pathol. 1999; 111 (suppl. 1): 94-103.
7. Russian source
8. Russian source
9. Russian source
10. Silverman G. J., Weisman S. Rituximab therapy and autoimmune disorders. Arthr. and Rheum. 2003; 48 (6): 1484-1491.
11. Cohen S. B. B-cell depletion for rheumatic disease: where are we? Med. Gen. Med. 2005; 7 (2): 1-13.
12. Russian source
13. Harris N., Jaffe E., Diebold J. et al. The World Health Organization classification of neoplastic diseases of the hematopoetic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November, 1997. Ann. Oncol. 1999; 10: 1419-1432.
14. Carbone P. P., Kaplan H. S., Musshoff K. et al. Report on the Committee on Hodgkin's Disease Studying Classification. Cancer Res. 1971; 31: 1860-1861.
15. Serror R., Sordet C., Guillevin L. et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann. Rheum. Dis. 2007; 66 (3): 351-358.
16. Pijpe P., van Imhoff G. W., Spijkervet F. K. et al. Rituximab treatment in patients with Sjogren's syndrome: an open-label phase II study. Arthr. and Rheum. 2005; 52 (9): 2740-2750.
17. Deyauchelle-Pensec V., Pennée Y., Morvan J. et al. Improvement of Sjogren's syndrome after two infusions of Rituximab (Anti-CD20). Arthr. and Rheum. 2007; 57 (2): 310-317.
18. Cavalli F., Isaacson P. G., Gascoyne R. D., Zueca E. MALT Lymphas. Hematology 2001; 241-258.
19. Voulgarelis M., Giannjuli S., Tzioufas A. G., Moutsopoulos H. M. Long term remission of Sjogren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann. Rheum. Dis. 2006; 65: 1033-1037.
20. Russian source
21. Russian source
22. Edwards J. C., Szczepanski L., Filipowicz-Sosnovska A. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004; 350: 2572-2581.
23. Zaja F., De Vita S., Mazzaro C. et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101 (10): 3827-3834.
24. Cohen H., Green S., Jones S. et al. Lack of efficacy of rituximab in a patient with essential mixed cryoglobulinemia. Rheumatology 2007; 46 (2): 366-367.
25. Russian source
26. Russian source
27. Somer B. G., Tsai D. E., Downs L. et al. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthr. and Rheum. 2003; 49 (3): 394-398.
28. Martin T., Weber J.-C., Levallois H. et al. Salivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B-cell. Arthr. and Rheum. 2000; 43: 908-916.
29. Russian source
30. Russian source